Recombinant human lung surfactant
Executive Summary
Scios Nova reacquires manufacturing and worldwide marketing rights from Genentech in exchange for an undisclosed amount of newly issued common stock. "Upon marketing approval, Scios Nova will issue additional common stock and will pay [Genentech] a royalty on sales of recombinant hLS," a Nov. 2 release notes. The original deal dates back to 1989.